QTRX vs. EYPT, PACB, LAB, CTKB, NAUT, DH, LYEL, AUNA, MLYS, and PHAR
Should you be buying Quanterix stock or one of its competitors? The main competitors of Quanterix include EyePoint Pharmaceuticals (EYPT), Pacific Biosciences of California (PACB), Standard BioTools (LAB), Cytek Biosciences (CTKB), Nautilus Biotechnology (NAUT), Definitive Healthcare (DH), Lyell Immunopharma (LYEL), Auna (AUNA), Mineralys Therapeutics (MLYS), and Pharming Group (PHAR). These companies are all part of the "medical" sector.
EyePoint Pharmaceuticals (NASDAQ:EYPT) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.
EyePoint Pharmaceuticals received 184 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 69.81% of users gave EyePoint Pharmaceuticals an outperform vote while only 61.66% of users gave Quanterix an outperform vote.
Quanterix has a net margin of -28.82% compared to Quanterix's net margin of -157.77%. EyePoint Pharmaceuticals' return on equity of -10.39% beat Quanterix's return on equity.
99.4% of EyePoint Pharmaceuticals shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 13.1% of EyePoint Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of Quanterix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Quanterix has higher revenue and earnings than EyePoint Pharmaceuticals. Quanterix is trading at a lower price-to-earnings ratio than EyePoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
EyePoint Pharmaceuticals has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.
EyePoint Pharmaceuticals currently has a consensus target price of $33.71, suggesting a potential upside of 169.28%. Quanterix has a consensus target price of $30.60, suggesting a potential upside of 76.37%. Given Quanterix's higher possible upside, research analysts clearly believe EyePoint Pharmaceuticals is more favorable than Quanterix.
In the previous week, EyePoint Pharmaceuticals had 17 more articles in the media than Quanterix. MarketBeat recorded 34 mentions for EyePoint Pharmaceuticals and 17 mentions for Quanterix. EyePoint Pharmaceuticals' average media sentiment score of 1.07 beat Quanterix's score of 0.47 indicating that Quanterix is being referred to more favorably in the news media.
Summary
EyePoint Pharmaceuticals beats Quanterix on 10 of the 19 factors compared between the two stocks.
Get Quanterix News Delivered to You Automatically
Sign up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quanterix Competitors List
Related Companies and Tools
